BRIEF published on 12/13/2024 at 12:02, 11 months 22 days ago Citigroup reduces its stake in GENEURO SA Euronext Paris Sale Of Shares Threshold Crossing GeNeuro SA Citigroup
BRIEF published on 12/06/2024 at 18:35, 11 months 29 days ago GeNeuro's New Precision Medicine for ALS Unveiled Precision Medicine GeNeuro ALS Treatment GNK-301 HERV-K ENV
PRESS RELEASE published on 12/06/2024 at 18:30, 11 months 29 days ago Inside Information / Other news releases GeNeuro presents groundbreaking findings on precision medicine for ALS patients with GNK-301 at the 35th International Symposium on ALS/MND. Research highlights potential of targeting HERV-K ENV to transform ALS treatment Precision Medicine ALS GeNeuro GNK-301 HERV-K ENV
BRIEF published on 11/06/2024 at 09:48, 1 year ago Crossing of thresholds by Invus Public Equities in GENEURO SA Euronext Paris Capital Increase Crossing Thresholds GeNeuro SA Invus Public Equities
BRIEF published on 06/28/2024 at 07:05, 1 year 5 months ago GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome Business Strategy Clinical Test GeNeuro Temelimab Post-Covid-19 Syndrome
PRESS RELEASE published on 06/28/2024 at 07:00, 1 year 5 months ago Inside Information / Other news releases GeNeuro announces results of the GNC-501 study addressing post-COVID-19 neuropsychiatric syndromes. Initial findings show no significant improvement with temelimab treatment compared to placebo GeNeuro Temelimab Neuropsychiatric Post-Covid-19 Syndrome GNC-501 Study
BRIEF published on 06/14/2024 at 18:35, 1 year 5 months ago GeNeuro Announces Unanimous Approval of Resolutions at AGM Shareholders Biopharmaceutical AGM Resolutions GeNeuro
PRESS RELEASE published on 06/14/2024 at 18:30, 1 year 5 months ago Inside Information / Other news releases GeNeuro shareholders approve all resolutions proposed at 2024 AGM, including annual report, re-election of Board members, and compensation approval. 81.54% share capital represented at the meeting Shareholders Compensation AGM Resolutions GeNeuro
BRIEF published on 05/29/2024 at 19:32, 1 year 6 months ago GeNeuro: Information on the General Meeting of June 12, 2024 Shareholders Biopharmaceutical Multiple Sclerosis General Assembly GeNeuro
PRESS RELEASE published on 05/29/2024 at 19:27, 1 year 6 months ago Inside Information / Other news releases GeNeuro announces availability of documents for the annual shareholders’ meeting on June 12, 2024 in Geneva, Switzerland. Documents accessible online and at company headquarters Shareholders' Meeting Annual Meeting GeNeuro Geneva Documents Availability
Published on 12/05/2025 at 02:35, 7 hours 44 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 9 hours 19 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 14 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 19 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:40, 38 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 49 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 13 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour 18 minutes ago Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 08:45, 1 hour 34 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 19 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 34 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 35 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
